1.1 List of Tables 13
1.2 List of Figures 22

2 Introduction 23
2.1 Cardiovascular Surgery Devices Overview 23

3 Products under Development 24
3.1 Cardiovascular Surgery Devices - Pipeline Products by Stage of Development 24
3.2 Cardiovascular Surgery Devices - Pipeline Products by Segment 25
3.3 Cardiovascular Surgery Devices - Pipeline Products by Territory 26
3.4 Cardiovascular Surgery Devices - Pipeline Products by Regulatory Path 27
3.5 Cardiovascular Surgery Devices - Pipeline Products by Estimated Approval Date 28
3.6 Cardiovascular Surgery Devices - Ongoing Clinical Trials 29

4 Cardiovascular Surgery Devices - Pipeline Products under Development by Companies 30
4.1 Cardiovascular Surgery Devices Companies - Pipeline Products by Stage of Development 30
4.2 Cardiovascular Surgery Devices - Pipeline Products by Stage of Development 35

5 Cardiovascular Surgery Devices Companies and Product Overview 40
5.1 3DT Holdings LLC Company Overview 40
5.1.1 3DT Holdings LLC Pipeline Products & Ongoing Clinical Trials Overview 40
5.2 AblaCor Medical Corporation Company Overview 41
5.2.1 AblaCor Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 41
5.3 Adagio Medical Inc. Company Overview 43
5.3.1 Adagio Medical Inc. Pipeline Products & Ongoing Clinical Trials Overview 43
5.4 Advanced Catheter Therapies Inc Company Overview 46
5.4.1 Advanced Catheter Therapies Inc Pipeline Products & Ongoing Clinical Trials Overview 46
5.5 AdvanSource Biomaterials Corporation Company Overview 48
5.5.1 AdvanSource Biomaterials Corporation Pipeline Products & Ongoing Clinical Trials Overview 48
5.6 AFreeze GmbH Company Overview 49
5.6.1 AFreeze GmbH Pipeline Products & Ongoing Clinical Trials Overview 49
5.7 AngioDymics Inc Company Overview 53
5.7.1 AngioDymics Inc Pipeline Products & Ongoing Clinical Trials Overview 53
5.8 Apaxis Medical Inc Company Overview 56
5.8.1 Apaxis Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 56
5.9 APK Advanced Medical Technologies, Inc. Company Overview 59
5.9.1 APK Advanced Medical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 59
5.10 Applied Medical Resources Corporation Company Overview 60
5.10.1 Applied Medical Resources Corporation Pipeline Products & Ongoing Clinical Trials Overview 60
5.11 Atrian Medical Ltd Company Overview 61
5.11.1 Atrian Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 61
5.12 AtriCure Inc Company Overview 62
5.12.1 AtriCure Inc Pipeline Products & Ongoing Clinical Trials Overview 62
5.13 Axcelon Biopolymers Corp. Company Overview 69
5.13.1 Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 69
5.14 Baylis Medical Company Inc Company Overview 70
5.14.1 Baylis Medical Company Inc Pipeline Products & Ongoing Clinical Trials Overview 70
5.15 Beth Israel Deaconess Medical Center Inc Company Overview 72
5.15.1 Beth Israel Deaconess Medical Center Inc Pipeline Products & Ongoing Clinical Trials Overview 72
5.16 Bioretec Ltd Company Overview 74
5.16.1 Bioretec Ltd Pipeline Products & Ongoing Clinical Trials Overview 74
5.17 Boston University Company Overview 75
5.17.1 Boston University Pipeline Products & Ongoing Clinical Trials Overview 75
5.18 Breethe, Inc. Company Overview 76
5.18.1 Breethe, Inc. Pipeline Products & Ongoing Clinical Trials Overview 76
5.19 CardiacAssist Inc Company Overview 77
5.19.1 CardiacAssist Inc Pipeline Products & Ongoing Clinical Trials Overview 77
5.20 CardioPolymers Inc Company Overview 78
5.20.1 CardioPolymers Inc Pipeline Products & Ongoing Clinical Trials Overview 78

6 Cardiovascular Surgery Devices- Recent Developments 228
6.1 Nov 26, 2019: MiMedx announces Securities and Exchange Commission Settlement 228
6.2 Nov 26, 2019: MiMedx mes William "Butch" Hulse as General Counsel and Secretary 228
6.3 Nov 26, 2019: SEC charges biotech company and executives with accounting fraud 229
6.4 Nov 20, 2019: First cryoballoon ablation procedures performed using the VersaCross Transseptal Solution 230
6.5 Nov 19, 2019: Hancock Jaffe Medical Team to make presentations at 46th Annual VEITH Vascular Symposium 230

7 Appendix 469
7.1 Methodology 469
7.2 About GlobalData 472
7.3 Contact Us 472
7.4 Disclaimer 472